Assertio Holdings, Inc.宣布将其旗下消炎药Indocin、抗癫痫药Sympazan、镇痛喷雾Sprix、偏头痛治疗药Cambia、镇痛药Zipsor及风湿性关节炎治疗药Otrexup等六款药品资产组合，以3500万美元现金加未来盈利分成的条件，整体出售给制药公司Cosette。此次交易标志着Assertio进一步聚焦核心业务战略的落地。通过剥离非核心资产，公司计划优化产品线结构并强化现金流。交易完成后，Assertio将更专注于神经系统疾病与疼痛管理领域的高增长业务板块。
Assertio Holdings, Inc.宣布将其旗下消炎药Indocin、抗癫痫药Sympazan、镇痛喷雾Sprix、偏头痛治疗药Cambia、镇痛药Zipsor及风湿性关节炎治疗药Otrexup等六款药品资产组合，以3500万美元现金加未来盈利分成的条件，整体出售给制药公司Cosette。此次交易标志着Assertio进一步聚焦核心业务战略的落地。通过剥离非核心资产，公司计划优化产品线结构并强化现金流。交易完成后，Assertio将更专注于神经系统疾病与疼痛管理领域的高增长业务板块。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.